Literature DB >> 36186237

Applications of Dexmedetomidine in Palliative and Hospice Care.

Rafael Lemus1, Natalie L Jacobowski2,3, Lisa Humphrey1,2,3,4, Joseph D Tobias4.   

Abstract

Although the use of dexmedetomidine is currently approved by the US Food and Drug Administration in the adult population for monitored anesthesia care and sedation during mechanical ventilation, clinical experience suggests the potential application of dexmedetomidine in the palliative care arena. The medication can provide sedation with lower risk of delirium, control or minimize the adverse effects of other medications, and augment analgesia from opioids. We conducted a computerized bibliographic search of the literature regarding dexmedetomidine use for the treatment of pain and provision of sedation during palliative and hospice care in adult and pediatric patients. The objective was to provide a general descriptive account of the physiologic effects of dexmedetomidine and review its potential applications in the field of palliative and hospice care in adult and pediatric patients. The sedative and analgesic effects of dexmedetomidine have been well studied in animal and human models. Published experience from both single case reports and small case series has demonstrated the potential therapeutic applications of dexmedetomidine in palliative and hospice care. In addition to intravenous administration, case reports have demonstrated its successful use by both the intranasal and subcutaneous routes. Although these experiences have suggested its safety and efficacy, larger series and additional clinical experience with prospective comparison to other agents are needed to further define its efficacy and role in palliative and hospice care. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org 2022.

Entities:  

Keywords:  dexmedetomidine; hospice care; palliative care; sedation

Year:  2022        PMID: 36186237      PMCID: PMC9514772          DOI: 10.5863/1551-6776-27.7.587

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  61 in total

1.  Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit.

Authors:  R M Venn; C J Bradshaw; R Spencer; D Brealey; E Caudwell; C Naughton; A Vedio; M Singer; R Feneck; D Treacher; S M Willatts; R M Grounds
Journal:  Anaesthesia       Date:  1999-12       Impact factor: 6.955

2.  Dexmedetomidine facilitates the withdrawal of ventilatory support in palliative care.

Authors:  Christopher D Kent; Brian S Kaufman; Joseph Lowy
Journal:  Anesthesiology       Date:  2005-08       Impact factor: 7.892

3.  The analgesic action of dexmedetomidine--a novel alpha 2-adrenoceptor agonist--in healthy volunteers.

Authors:  Marja-Leena Jaakola; Markku Salonen; Risto Lehtinen; Harry Scheinin
Journal:  Pain       Date:  1991-09       Impact factor: 6.961

4.  Low-Dose Nocturnal Dexmedetomidine Prevents ICU Delirium. A Randomized, Placebo-controlled Trial.

Authors:  Yoanna Skrobik; Matthew S Duprey; Nicholas S Hill; John W Devlin
Journal:  Am J Respir Crit Care Med       Date:  2018-05-01       Impact factor: 21.405

5.  The effects of increasing plasma concentrations of dexmedetomidine in humans.

Authors:  T J Ebert; J E Hall; J A Barney; T D Uhrich; M D Colinco
Journal:  Anesthesiology       Date:  2000-08       Impact factor: 7.892

6.  Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.

Authors:  Kathy A Sheehy; Julia C Finkel; Deepika S Darbari; Michael F Guerrera; Zenaide M N Quezado
Journal:  Pain Pract       Date:  2015-07-23       Impact factor: 3.183

7.  A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats.

Authors:  C Correa-Sales; B C Rabin; M Maze
Journal:  Anesthesiology       Date:  1992-06       Impact factor: 7.892

8.  The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects.

Authors:  Laura E Nelson; Jun Lu; Tianzhi Guo; Clifford B Saper; Nicholas P Franks; Mervyn Maze
Journal:  Anesthesiology       Date:  2003-02       Impact factor: 7.892

9.  An analysis of the safety and efficacy of dexmedetomidine in posterior spinal fusion surgery for adolescent idiopathic scoliosis: a prospective randomized study.

Authors:  Ankith Naduvanahalli Vivekanandaswamy; Ajoy Prasad Shetty; Rishi Mugesh Kanna; Rajasekaran Shanmuganathan
Journal:  Eur Spine J       Date:  2020-07-21       Impact factor: 3.134

10.  Pertussis toxin-mediated ribosylation of G proteins blocks the hypnotic response to an alpha 2-agonist in the locus coeruleus of the rat.

Authors:  C Correa-Sales; K Reid; M Maze
Journal:  Pharmacol Biochem Behav       Date:  1992-11       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.